Oncology News

In patients with chronic hepatitis B infection, treatment with tenofovir disoproxil may significantly reduce the risk for hepatocellular carcinoma, according to study findings published in The Journal of Infectious Diseases.

Medication nonadherence among patients with hepatitis B increased the risk for hepatocellular carcinoma, cirrhotic complications and all-cause mortality, according to recently published data.

OBI Pharma received FDA orphan drug designation for OBI-3424 for the treatment of hepatocellular carcinoma, according to a press release.

Liver disease-related mortality rates varied significantly by geographic region in the Untied States with some of the highest rates in the South and the West, in areas with higher Hispanic populations, and areas of lower household income, according to a recently published study.

Results of a recent study showed that nonalcoholic steatohepatitis was the most rapidly growing cause of hepatocellular carcinoma among U.S. patients listed for liver transplantation.

The number of liver transplantations due to hepatitis C-related decompensated cirrhosis and hepatocellular carcinoma declined rapidly over the last 3 years while posttransplant survival has improved, according to data from the European Liver Transplant Registry .

This year at the Digestive Disease Meeting, physicians noted a significant increase in studies focused on the growing obesity epidemic and the gut microbiome as related to gastrointestinal complications. Additionally, the meeting included several presentations on nonalcoholic fatty liver disease treatment, outcomes in hepatitis C and hepatitis B, early detection of liver cancer, and reviews on recent obesity and gut microbiome studies.

Children with standard-risk hepatoblastoma who received sodium thiosulfate 6 hours after cisplatin chemotherapy had a 48% lower incidence of cisplatin-induced hearing loss, according to phase 3 results from the SIOPEL 6 clinical trial published in The New England Journal of Medicine.

Researchers determined racial and ethnic differences that correlated with early detection of hepatocellular carcinoma and receipt of curative treatment, which could be used as intervention targets to improve patient outcomes.

WASHINGTON — In this exclusive industry perspective from Digestive Disease Week 2018, Kevin Conroy, CEO of Exact Sciences, discusses the company’s noninvasive Cologuard colon cancer test and recent data on a new noninvasive test for the detection of liver cancer.